Literature DB >> 7850990

Determinants of serum 1,25-dihydroxyvitamin D concentration in healthy premenopausal subjects.

S C Ho1, D Mac Donald, C Chan, Y K Fan, S S Chan, R Swaminathan.   

Abstract

Concentrations of serum phosphate and parathyroid hormone (PTH) are well known regulators of the production of 1,25-dihydroxyvitamin D (1,25-(OH)2D) and acidosis is known to affect the serum concentration of 1,25-(OH)2D. However, the factors that play a role in the regulation of serum 1,25-(OH)2D concentration in healthy subjects have not been fully evaluated. The associations of ionised calcium, pH, serum concentration of phosphate, PTH, 25-hydroxyvitamin D (25-OHD) and serum 1,25-(OH)2D were examined in 296 healthy premenopausal women (age range 17-40 years). Calculation of partial correlation coefficients showed that serum 1,25-(OH)2D was significantly correlated with phosphate (r = -0.148, P < 0.01), pH (r = 0.221, P < 0.001) and PTH (r = 0.136. P < 0.01). Ionised calcium was not related to serum 1,25-(OH)2D. When the results were stratified according to quartiles based on serum 1,25-(OH)2D concentration, significant trends (by analysis of variance) were seen in phosphate, pH, age, albumin and 25-OHD. Stepwise multiple regression analysis showed that phosphate and pH were the major contributors of serum 1,25-(OH)2D levels. There was a small contribution from PTH and 25-OHD. The results suggest that in young healthy premenopausal women plasma phosphate and pH may be important determinants of serum 1,25-(OH)2D concentration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7850990     DOI: 10.1016/0009-8981(94)90085-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature.

Authors:  R F Ritchie; G E Palomaki; L M Neveux; O Navolotskaia
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study.

Authors:  C P Williams; D F Child; P R Hudson; G K Davies; M G Davies; R John; P S Anandaram; A R De Bolla
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.